KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBT Margin (2018 - 2026)

Castle Biosciences' EBT Margin history spans 8 years, with the latest figure at 3.12% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 1225.0% to 3.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 8.57%, a 1507.0% decrease, with the full-year FY2025 number at 8.57%, down 1507.0% from a year prior.
  • EBT Margin hit 3.12% in Q4 2025 for Castle Biosciences, down from 0.46% in the prior quarter.
  • Over the last five years, EBT Margin for CSTL hit a ceiling of 9.65% in Q3 2024 and a floor of 91.2% in Q1 2022.
  • Historically, EBT Margin has averaged 25.45% across 5 years, with a median of 14.97% in 2023.
  • Biggest five-year swings in EBT Margin: tumbled -7244bps in 2022 and later soared 6603bps in 2024.
  • Tracing CSTL's EBT Margin over 5 years: stood at 60.53% in 2021, then increased by 11bps to 53.63% in 2022, then soared by 93bps to 3.84% in 2023, then soared by 338bps to 9.14% in 2024, then plummeted by -134bps to 3.12% in 2025.
  • Business Quant data shows EBT Margin for CSTL at 3.12% in Q4 2025, 0.46% in Q3 2025, and 0.17% in Q2 2025.